Fast Biopharma

Executive Summary

Fast Biopharma is a UK-based biopharmaceutical company pioneering therapeutics that inhibit a key pathway driving unwanted cell death in a range of severe diseases. Cell death is a central contributor to morbidity in conditions such as acute organ injury, neurodegenerative disorders, and inflammatory diseases. By blocking this major pathway, Fast Biopharma aims to prevent or reduce tissue damage and improve patient outcomes. The company’s platform leverages deep understanding of apoptosis and necroptosis mechanisms to develop novel antibody and biologic-based therapies. Founded in 2020 and based in London, Fast Biopharma operates at the intersection of cutting-edge cell biology and drug development, targeting high unmet medical needs with significant market potential. While still in early stages—with no disclosed pipeline milestones, funding rounds, or clinical trials—the scientific rationale underpinning Fast Biopharma’s approach is compelling. The ability to modulate cell death could yield breakthrough therapies applicable across multiple indications. The company’s progress will depend on advancing its lead candidates into preclinical development, securing financing, and establishing strategic partnerships. Given the early nature of the platform, significant execution risk remains, but the therapeutic promise positions Fast Biopharma as a potential leader in the cell death modulation space.

Upcoming Catalysts (preview)

• TBDCompletion of Lead Optimization and Preclinical Proof-of-Concept Studies40% success
• TBDIND-Enabling Toxicology Studies Initiation30% success
• TBDSeries A Funding or Strategic Partnership Announcement50% success